These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36528831)

  • 1. Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes.
    Ma C; Bao Y; Xu J; Xiao B; Li H
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):47-62. PubMed ID: 36528831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
    Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
    Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-related gene-located DNA methylation in lower-grade glioma: Prognosis and tumor microenvironment.
    Zhu L; Yuan F; Wang X; Zhu R; Guo W
    Cancer Biomark; 2024; 40(2):185-198. PubMed ID: 38578883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cuproptosis-based prognostic model for predicting survival in low-grade glioma.
    Zhao Z; Ma Y; Liu Y; Chen Z; Zheng J
    Aging (Albany NY); 2024 May; 16(10):8697-8716. PubMed ID: 38738989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
    Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
    Front Oncol; 2021; 11():650153. PubMed ID: 34055619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Critical m
    Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
    Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 10. Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma.
    Qiao Q; Wang Y; Zhang R; Pang Q
    Transl Cancer Res; 2022 Jul; 11(7):2157-2174. PubMed ID: 35966301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
    Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
    BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma.
    Liu J; Deng W; Xiao Z; Huang X; Lin M; Long Z
    J Immunol Res; 2022; 2022():8976179. PubMed ID: 36157883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
    Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
    Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
    Yu H; Gong M; Qi J; Zhao C; Niu W; Sun S; Li S; Hong B; Qian J; Wang H; Chen X; Fang Z
    BMC Cancer; 2022 Aug; 22(1):885. PubMed ID: 35964070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
    Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
    Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
    [No Abstract]   [Full Text] [Related]  

  • 16. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
    Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
    PeerJ; 2024; 12():e16874. PubMed ID: 38406287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A disulfidptosis-associated long noncoding RNA signature to predict low-grade glioma classification, prognosis, tumor microenvironment, and therapy regimens: Observational study.
    Qin X; Chen Z; Wu L; Ding R
    Medicine (Baltimore); 2024 Aug; 103(34):e39316. PubMed ID: 39183405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.